b r i e f c o m m u n i c at i o n s
Tauopathies are a group of neurodegenerative diseases, including Alzheimer's disease (AD), progressive supranuclear palsy, corticobasal degeneration, Pick's disease and FTDP-17, that are characterized by altered metabolism and deposition of the microtubule-associated protein tau 1 . Alternative splicing of exon 10 of the microtubule-associated protein tau (MAPT) gene results in tau isoforms containing either three or four microtubule-binding repeats (3R and 4R, respectively) 2 . Discovery of silent and intronic mutations leading to an increased 4R/3R ratio in families affected by revealed that an imbalance in 4R and 3R in favor of the 4R isoform is sufficient to cause neurodegeneration with personality disturbances, dementia and motor dysfunction.
HD is an autosomal dominant neurodegenerative disorder characterized by involuntary movements, psychiatric symptoms and dementia that is caused by an expanded CAG repeat in exon 1 of the huntingtin (HTT) gene 4 . HD thus belongs to the group of dominant trinucleotide repeat diseases, which include many other CAG repeat disorders, such as spinocerebellar ataxia type 1 (SCA1), SCA2, SCA3, SCA6, SCA7, SCA12, SCA17, dentatorubropallidoluysian atrophy and spinobulbar muscular atrophy, as well as the CUG repeat disorders SCA8 and myotonic dystrophy type 1 (ref. 5) . A key element in the pathogenesis of myotonic dystrophy type 1 is the binding of splicing factors by the mutant CUG transcript, thus leading to alternative splicing aberrations in multiple genes 6 . Notably, CAG repeats have recently been shown to mimic CUG repeats in the misregulation of alternative splicing 7 . As it has also been very recently reported that aberrant splicing contributes to the generation of the highly toxic short-N-terminal species of HTT 8 , it is conceivable that splicing alterations contribute substantially to HD pathogenesis.
Here we address whether the neurodegeneration-causing increase in 4R/3R tau mRNA ratio occurs in HD. To test this, we performed quantitative RT-PCR from RNA extracted from striatum and cortex of subjects with HD and healthy control subjects. The number of tau mRNA copies per nanogram of total RNA was equivalent in control subjects and in subjects with HD in both striatum and cortex (Fig. 1a) . However, in the striatum of control subjects, 3R tau mRNA isoforms predominated over 4R mRNA isoforms (59.1% versus 40.9%), whereas in HD samples, the proportion was shifted toward a higher content of 4R mRNA isoforms (46.3% versus 53.7%). Accordingly, the 4R/3R isoform ratio was dramatically increased in HD samples compared to controls (1.77-fold increase, P = 0.002). In the cortex, 3R tau mRNA isoforms predominated over 4R mRNA isoforms both in control and in HD samples. However, as the difference between 3R and 4R mRNA content was higher in control subjects (62.8% versus 37.2%) than in subjects with HD (56.3% versus 43.7%), the 4R/3R ratio was also significantly increased in HD cortex (1.43-fold increase, P = 0.015). To rule out any influence of the postmortem interval in this result, we confirmed that the 4R/3R tau ratio stayed constant in RNAs from control and HD RNA samples that were stored for up to 48 h at 4 °C to force a decrease in RNA integrity (Supplementary Fig. 1 ).
We then used antibodies specific to the 3R and 4R protein isoforms (RD3 and RD4, respectively) to explore by western blotting whether the increase in the 4R/3R mRNA ratio results in an equivalent imbalance in tau protein isoforms. HD samples showed a clear increase in 4R isoform levels in striatum and cortex and a clear decrease in 3R isoform levels, particularly in striatum (Fig. 1b) . In good agreement with the mRNA data, the increase in 4R/3R ratio was higher in striatum than in cortex (3.08-fold increase, P = 0.006 and 2.1-fold increase, P = 0.013; respectively). Notably, whereas total tau content (as measured with Tau5 antibody) was similar in striatum of control subjects and subjects with HD, we observed a clear increase in total tau levels in the cortex of subjects with HD (1.52-fold increase, P = 0.016) with the appearance of additional low-molecular-weight (35 and 39 kDa) truncated forms of tau. We also observed this increase and the appearance of the 35-and 39-kDa bands with the 5E2 antibody that also recognizes total tau, thus confirming specificity of the low-molecular-weight bands (Supplementary Fig. 2 ).
An imbalance of tau isoforms containing either three or four microtubule-binding repeats causes frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) in families with intronic mutations in the MAPT gene. Here we report equivalent imbalances at the mRNA and protein levels and increased total tau levels in the brains of subjects with Huntington's disease (HD) together with rod-like tau deposits along neuronal nuclei. These tau nuclear rods show an ordered filamentous ultrastructure and can be found filling the neuronal nuclear indentations previously reported in HD brains. Finally, alterations in serine/arginine-rich splicing factor-6 coincide with tau missplicing, and a role of tau in HD pathogenesis is evidenced by the attenuation of motor abnormalities of mutant HTT transgenic mice in tau knockout backgrounds. We then performed immunohistochemistry with the 4R-specific antibody (RD4) and with antibodies that recognize total tau (Tau5 and HT-7). Notably, the three antibodies detected rod-like tau deposits that partially or totally spanned the neuronal nuclear space (Fig. 1c and Supplementary Fig. 3 ). These neuronal tau nuclear rods (TNRs) were detected both in striatum and in cortex of each analyzed HD brain (n = 24), with abundance ranging from moderate to very high (Supplementary Table 1) . On the contrary, in striatum of the control brains (n = 23), TNRs were virtually absent: they were detected in only three or fewer cases, depending on the antibody, and they were always scarce. The incidence of TNRs in cortex of the control brains was similar, although the abundance was slightly higher. Apart from TNRs, the three antibodies detected granular cytoplasmic tau deposits, which often form perinuclear rings in cortical and striatal neurons, in subjects with HD ( Fig. 1c and Supplementary Fig. 3) ; these deposits were much less abundant in control subjects. We then wondered whether the TNRs found in brains of subjects with HD could also be found in those of individuals with a classic tauopathy. For this, we stained hippocampus of ten brains of subjects with AD with the RD4, Tau5 and HT-7 antibodies, and we found that TNRs are also present in AD hippocampus and seemed to be more abundant at early Braak stages with low or mild neurofibrillary tangle pathology (Fig. 1d) . Figure 1 Increased 4R/3R tau isoform ratio and total tau protein content in HD brains, presence of TNRs in HD (and AD) brains and analysis of SRSF6 splicing factor in HD brains and in transfected human neuroblastoma SH-SY5Y cells. (a) Quantitative RT-PCR analysis of total tau mRNA and of 3R and 4R mRNA isoforms in striatum and cortex of subjects with HD (striatum, n = 5 for control and n = 9 for HD; cortex, n = 9 for control and n = 10 for HD; Student's t-test; **P < 0.01, *P < 0.05; only samples with RNA integrity number (RIN) above 5 were included in the analysis). (b) Western blot analysis of 3R and 4R tau isoforms with the RD3-and RD4-specific antibodies and of total tau with the Tau5 antibody in total homogenates from striatum and cortex of control and HD brains (the position of the 49-kDa molecular weight marker is indicated; < signs indicate the truncated 35-and 39-kDa bands; striatum, n = 13 for control and n = 16 for HD; cortex, n = 11 for control and n = 11 for HD; Mann-Whitney U-test, *P < 0.05, **P < 0.01). 
As tau lesions in classic tauopathies such as progressive supranuclear palsy or Pick's disease, regardless of a shift in tau isoforms toward predominantly 4R or predominantly 3R, are not exclusively composed of 3R or 4R isoforms, we reasoned that TNRs in striatum and cortex of patients with HD could also contain 3R. We confirmed this by immunohistochemistry with the RD3 antibody ( Supplementary  Fig. 3 and Supplementary Table 1) . Similarly, the comparison of the Sarkosyl-soluble and Sarkosyl-insoluble tau fractions in cortex of control subjects and patients with HD, apart from revealing a tendency to a higher ratio of insoluble to soluble total tau in HD than in control samples (Supplementary Fig. 4a) , also confirmed the presence of both isoforms in the Sarkosyl-insoluble fraction ( Supplementary  Fig. 4b and data not shown). However, the Sarkosyl-insoluble tau in HD brains was much less abundant than was typically observed in AD samples ( Supplementary Fig. 4a ), and it did not contain phosphorylated tau (Supplementary Fig. 4c )-as expected, as tau is not hyperphosphorylated in cortex of HD brains ( Supplementary  Fig. 4d ). In good agreement with these results, we did not detect TNRs by immunohistochemistry with antibodies that recognize phosphorylated epitopes of tau such as AT-8 or PHF-1. However, we did detect TNRs in HD brains via immunohistochemistry with the T22 antibody, which recognizes oligomeric tau (Fig. 1e) .
The shape and localization of TNRs suggested that they might coincide with the neuronal nuclear indentations detected by electron microscopy in the early 1980s, before the identification of the mutation underlying HD, in frontal cortex and striatum of subjects with HD but not in nonchoreic control subjects 9, 10 ; these indentations are also seen in patients with dentatorubropallidoluysian atrophy 11 and in cell and mouse models of polyglutamine disease [12] [13] [14] . To confirm that TNRs span the neuronal nuclear space, we performed confocal analysis of brain sections from individuals with HD who were subjected to HT-7 immunofluorescence and DAPI nuclear counterstaining. DAPI staining revealed the presence of nuclear grooves that are filled by HT-7-positive TNRs (Fig. 1f) . Immunoelectron microscopy analysis further confirmed that TNRs occupy neuronal nuclear indentations and uncovered an ordered filamentous ultrastructure of the immunolabeled material (Fig. 1g) .
Tau and huntingtin (Htt) do not interact, as evidenced by the fact that they do not coimmunoprecipitate (Supplementary Fig. 5 ) and that they are restricted to their respective deposits, tau in the TNRs and Htt in the spheroid inclusion bodies (IBs). However, both histopathological hallmarks coincide in a subset of neurons. Double immunofluorescence with antibodies to tau (HT-7) and to ubiquitin, a covalently linked protein tag that is enriched in IBs, revealed that in cortex of an HD brain, 25.6% of the TNR-containing neurons also showed ubiquitin-positive nuclear IBs and 21.4% of the neurons with ubiquitin-positive nuclear IBs also showed TNRs (Supplementary Fig. 5 ).
Regarding the mechanism linking HTT mutation to tau alteration, Bates and colleagues 8 , using bioinformatic methods, recently predicted that the serine/arginine-rich splicing factor-6 (SRSF6, also known as SRp55) binds CAG repeats according to the 6-mer YRCRKM (T/C-A/G-C-A/G-G/T-A/C) consensus. They also showed, by molecular biology in vitro approaches, that SRSF6 binds the CAG repeat in mutant Htt mRNA. More recently, Krainer and colleagues 15 reported an extended 9-mer consensus sequence for SRSF6 binding, out of which the last eight nucleotides provide a perfect match with CAGCAGCA. Notably, SRSF6 is a well-known modulator of tau exon 10 alternative splicing 16 . Here we show that SRSF6 is altered in brains of subjects with HD, as it accumulates into Htt IBs (Fig. 1h) , its total abundance is increased, and a higher-molecular-weight band appears that is consistent with an increase in phosphorylated SRSF6 (Fig. 1i) . We confirmed this by western blot analysis with the 1H4 antibody, which recognizes phosphorylated SR (p-SR) proteins (Fig. 1i) . Recently, SRSF6 has been shown to favor production of 4R tau in SH-SY5Y human neuroblastoma cells 16 . We thus transfected SH-SY5Y cells with versions of N-terminal Htt with normal or expanded polyQ repeats fused to GFP, and we observed a tendency toward an increased 4R/3R tau mRNA ratio in cells transfected with expanded-polyQ Htt (Fig. 1j) . This effect was magnified and reached statistical significance upon cotransfection of SRSF6 (Fig. 1j) .
To explore whether an increased 4R/3R tau ratio and increased total tau levels confer a gain of toxicity in HD pathogenesis, we decided to cross R6/1 HD transgenic mice, which develop a rapidly progressing HD-like phenotype, into heterozygous (Mapt +/− ) and homozygous (Mapt −/− ) tau knockout backgrounds. We first confirmed that R6/1 mice show SRSF6 alterations similar to those seen in subjects with HD, such as accumulation in Htt IBs and increased phosphorylation (Fig. 2a,b) . We then verified that despite the fact that rodents express mainly 4R mRNA isoforms 17, 18 , R6/1 mice still show a tendency toward an increased 4R/3R ratio at both the mRNA and protein levels in striatum and cortex (Fig. 2c,d) . In addition, R6/1 mice show significantly increased 4R levels in striatum compared to wild-type (nontransgenic) mice (1.41-fold increase, P = 0.04), and they also show significantly increased total tau levels in striatum and cortex compared to wild-type mice (1.42-fold increase, P = 0.04 and 1.49-fold increase, P = 0.02; respectively, Fig. 2d) . We obtained similar results in HD94 mice, which have a milder, slowly progressing phenotype and a much longer lifespan than R6/1 mice. More precisely, we observed a similar increase in total tau levels in cortex of 20-month-old HD94 mice, along with a significant increase in the 4R/3R tau ratio both in striatum and in cortex ( Supplementary  Fig. 6 ). We also verified that, although less abundant than in human HD brains, TNRs are also present in the brains of R6/1 and HD94 mice (Fig. 2e,f) . Next, upon breeding Mapt +/− mice with R6/1 Mapt +/− mice, we obtained R6/1Mapt +/+ , R6/1Mapt +/− and R6/1Mapt −/− mice according to the expected Mendelian distribution. We monitored these mice for evolution of body weight and for behavioral characterization in activity cages (to appraise global motor activity) and in the accelerating rotarod apparatus (to assess motor coordination). As expected, we first verified that R6/1 Mapt +/− and R6/1 Mapt −/− mice showed partial and absolute reduction of tau levels, respectively (Fig. 2g) . Histopathological analysis also confirmed that TNRs can also be detected in R6/1 Mapt +/− mice but not in R6/1 Mapt −/− mice (Supplementary Fig. 7 ) and that Mapt gene dosage did not affect the number of striatal Htt IBs, although these were slightly smaller sized in R6/1 Mapt +/− and R6/1 Mapt −/− mice. SRSF6 accumulation in IBs and the number of cleaved caspase-3-positive cells in striatum were not affected by the tau knockout mutation either. Regarding functional readouts of R6/1 mice, the progressive body weight loss experienced by HD transgenic mice was similar in R6/1 Mapt +/+ , R6/1 Mapt +/− and R6/1 Mapt −/− mice (Fig. 2h) . However, R6/1 Mapt +/− and R6/1 Mapt −/− mice performed better than R6/1 Mapt +/+ mice in the rotarod test at early symptomatic (12 weeks) and fully symptomatic (16 weeks) ages (Fig. 2i) . Similarly, the significant hypoactivity observed in R6/1 Mapt +/+ mice at late symptomatic ages, as evidenced by a decrease in vertical counts and in ambulatory distance in the activity cage, was attenuated in R6/1 Mapt +/− and R6/1 Mapt −/− mice (Fig. 2j) . Together, the rotarod and activity cage results demonstrate that tau contributes to the motor phenotype of HTT transgenic mice.
npg b r i e f c o m m u n i c at i o n s
In summary, here we show that the HTT mutation leads to pathogenic tau alterations, namely an increase of the 4R/3R tau isoform ratio and an increase in total tau content. In addition, we found nuclearspanning rod-like tau deposits (TNRs) in HD brains, which we also found in AD brains. Finally, the attenuated motor phenotype of HTT transgenic mice with genetic tau reduction demonstrates a role of tau in HD pathogenesis. However, it should be noted that additional work needs to be done to elucidate whether the three key findings in this study-altered 4R/3R tau splicing resulting in an imbalance 4R and 3R isoforms, presence of TNRs and in vivo effects of reduced tau expression in mutant HTT transgenic mice-are functionally linked to each other. For instance, if TNRs were found in brains of individuals with FTPD-17 with intronic mutations, this would strongly suggest that an imbalance of 4R and 3R tau isoforms is sufficient to cause TNR formation. At this time, we do not know whether TNRs contribute to HD pathogenesis. One possible scenario is that an increased 4R/3R tau isoform ratio leads to altered microtubule dynamics and multiple subsequent intracellular alterations, such as a pathogenic disruption of axonal transport accompanied by a harmless bundling of microtubules from the centrosome, that induce a nuclear indentation with a high content of tau. In this case, formation of TNRs would not be pathogenic but rather a marker of altered microtubule dynamics as a consequence of an altered 4R/3R tau isoform ratio. Alternatively, TNRs might compromise the integrity of the nuclear envelope and/or lead to nuclear fragmentation and neuronal death. Most of these are testable hypotheses and, as mentioned, additional experiments will need to be done to explore the interconnection and precise pathophysiological implications of the findings reported here for HD brains and models. 
Future studies will also be required to determine whether similar tau alterations can be found in the other neurological disorders caused by an expanded CAG repeat (although we could not detect TNRs in cerebellum of a very limited number of SCA1 and SCA3 brains; Supplementary Fig. 8 ). If tau alterations are indeed specific for HD, this might be the reason why, unlike the SCAs, HD presents with basal ganglia-associated movement alterations and cortical dementia. Finally, the incidence of TNRs needs to be thoroughly analyzed in AD and the rest of the classic tauopathies, particularly those with accumulation of 4R tau and an imbalance of 4R and 3R isoforms, such as FTDP-17. Finally, our results suggest that either gene therapy-or small molecule-based tau-related therapies currently under development for FTDP-17 and other tauopathies 19, 20 might also be helpful for HD.
MeTHoDs
Methods and any associated references are available in the online version of the paper. Quantitative real-time RT-PCR. Total tissue RNA was extracted from striatum and cortex of subjects with HD and control subjects using the Maxwell 16 LEV simplyRNA Tissue Kit (Promega). The resulting total RNA (750 ng) was used for cDNA synthesis with a Super Script III First-Strand Synthesis SuperMix kit from Invitrogen (PN 11752250) followed by PCR with the amplification protocol 30 s at 95 °C + (5 s at 95 °C + 5 s at 60 °C) × 40 + (5 s at 60 °C + 5 s at 95 °C). Quantification was performed by real-time PCR using a CFX 384 System (Bio-Rad) in combination with SsoFast Eva Green (Bio-Rad), as per manufacturer's protocol, and 1 µL of primer pair was used. Data were analyzed by GenEx 5.3.7 software (Multid AnaLyses AB). The mRNA levels were normalized first relative to total RNA and then relative to the mean of 18S ribosome subunit, GADPH, β-actin and β-tubulin gene expression in each sample. The PCR primers used for human were the following: total tau forward 5′AGAGTCCAGTCGAAGATTGGGTC 3′, total tau reverse 5′ GGGTTTCAA TCTTTTTATTTCCTCC 3′; 4R tau forward 5′ GGTGCAGATAATTAATAAG AAGCTGGA 3′, 4R tau reverse 5′ GTGTTTGATATTATCCTTTGAGCCAC 3′; and 3R tau forward 5′ GAAGAATGTCAAGTCCAAGATCGG 3′, 3R tau reverse 5′ GACTATTTGCACCTTCCCGC 3′. The PCR primers used for mouse were the following: total tau forward 5′ AGGGAACATCCATCACAAGC 3′, total tau reverse 5′ TGGACTCTGTCCTTGAAGTCC 3′; 4R tau forward 5′ TGTCAGGTCGAAGATTGGCTC 3′, 4R tau reverse 5′ CTTATTAATTATCTGC ACCTTGCCAC 3′; and 3R tau forward 5′ GTCAGGTCGAAGATTGGCTCTACT 3′, 3R tau reverse 5′ GCTTGTAGACTATTTGCACCTTGC 3′. In human samples, to determine the ratio of the 4R/3R tau isoform expression in each sample by absolute quantitative PCR, the total tau, 4R tau and 3R tau amplicon obtained with the above-mentioned selective primers for total tau, 4R tau and 3R tau were inserted into a pMA-T plasmid that was provided by GeneART (Life Technologies). This pMA-T-Total Tau_4R Tau_3R Tau plasmid, containing one copy of each total tau, 4R tau and 3R tau amplicons, was digested with the AscI restriction enzyme and serially diluted to generate a calibration curve. As expected, the efficiency of the PCR reaction and the melting curve for each primer pair were the same using the standard pMA-T-Total Tau_4R Tau_3R Tau plasmid or human cDNA samples. To assess whether postmortem intervalrelated degradation differentially affects certain transcripts, samples from a subject with HD and a control subject were left at 4 °C for 24 and 48 h. Next, total tissue RNA was extracted, and quantitative real-time RT-PCR was performed.
Western blotting. The different human brain regions that were stored at −80 °C were ground with a mortar in a frozen environment with liquid nitrogen to prevent thaw of the samples. The resulting powder was homogenized. For mice, brains were quickly dissected on an ice-cold plate. Both extracts were prepared by homogenizing the brain areas in ice-cold extraction buffer consisting of 20 mM HEPES, pH 7.4, 100 mM NaCl, 20 mM NaF, 1% Triton X-100, 1 mM sodium orthovanadate, 1 µM okadaic acid, 5 mM sodium pyrophosphate, 30 mM β-glycerophosphate, 5 mM EDTA and protease inhibitors (2 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 10 µg/ml pepstatin). Samples were homogenized and centrifuged at 15,000g for 15 min at 4 °C. The resulting supernatant was collected, and protein content determined by Bradford assay. Fifteen micrograms of total protein were electrophoresed on 10% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane and blocked in TBS-T (150 mM NaCl, 20 mM Tris-HCl, pH 7.5, 0.05% Tween 20) supplemented with 5% nonfat dry milk.
Inclusion or exclusion of exon 10 results in unique amino acid sequences in the tubulin-binding domain of either 3R and 4R tau protein isoforms. This fact has allowed the generation by de Silva et al. 22 of monoclonal antibodies that distinguish with complete specificity the 4R and 3R tau protein isoforms. These antibodies are termed RD4 (1:1,000, clone 1E1/A6, 05-804 from Millipore) and RD3 (1:1,000, clone 8E6/C11, 05-803 from Millipore), respectively. Other employed antibodies were anti-tau clone Tau5 (1:1,000, 577801 from Calbiochem), anti-SRSF6 (1:1,000, LS-B5712 from LSBio), anti-p-SR clone 1H4 (1:1,000, MABE50 from Millipore), anti-tau clone 5E2 (1:1,000, 05-348 from Millipore), anti-PHF-1 (1:1,000, provided by P. Davies), anti-tau clone 7.51 (1:1,000, provided by M. Novak and C.M. Wischik), anti-tau clone AT8 (1:1,000, MN1020 from Thermo Scientific), anti-GADPH (1:2,000, ab9483 from Abcam) and β-actin clone AC-74 (1:4,000, A5316 from Sigma-Aldrich).
The membranes were incubated with the primary antibody overnight at 4 °C in TBST supplemented with 5% nonfat dried milk, washed in TBS-T and then incubated with secondary HRP-conjugated anti-mouse IgG (P0447 from DAKO Cytomation) and developed using the ECL detection kit (Perkin Elmer).
Immunohistochemistry and immunofluorescence. For human samples, formalin-fixed (4%, 24 h), paraffin-embedded tissue from cortex and striatum were used. Sections (5-µm thick) were mounted on superfrost-plus tissue slides (Menzel-Gläser) and deparaffinized.
Mice were killed using CO 2 and brains immediately removed and dissected on an ice-cold plate. Left hemispheres were processed for histology, placed in 4% paraformaldehyde in Sorensen's phosphate buffer (PFA) overnight and then immersed in 30% sucrose in PBS for 72 h. Once cryoprotected, the samples were included in OCT compound (Sakura Finetek Europe), frozen and stored at −80 °C until use. 30-µm sagittal sections were cut on a CM 1950 Ag Protect freezing microtome (Leica) and collected and stored free-floating in glycol containing buffer (30% glycerol, 30% ethylene glycol in 0.02 M phosphate buffer) at −20 °C. Subsequently, sections were immersed in 0.3% H 2 O 2 in methanol for 30 min to quench endogenous peroxidase activity and treated in 10 mM pH 6.0 citrate buffer heated by microwave for 15 min for antigen retrieval. For immunohistochemical staining, slides were blocked for 1 h in PBS containing 0.5% FBS, 0.3% Triton X-100 and 1% BSA (Sigma-Aldrich). Sections were incubated overnight at 4 °C in PBS containing 0.3% Triton X-100 and 1% BSA with the corresponding primary antibodies: RD4 clone 1E1/A6 (1:80, 05-804 from Millipore), anti-tau clone HT-7 (1:200, MN1000 from Thermo Scientific), anti-tau clone Tau5 (1:200, 577801 from Calbiochem), RD3 clone 8E6/C11 (1:4,000, 05-803 from Millipore), T22 recognizing oligomeric tau 23 (1:100, provided by R. Kayed), anti-SRSF6 (1:400, LS-B5712 from LSBio), anti-huntingtin clone EM48 (1:100, MAB5374 from Millipore) and anti-cleaved caspase-3 (1:50, 9661 from Cell Signaling). Finally, brain sections were incubated in avidin-biotin complex using the Elite Vectastain kit (Vector Laboratories). Chromogen reactions were performed with diaminobenzidine (SIGMAFAST DAB, Sigma) for 10 min. Sections were mounted on glass slides and coverslipped with Mowiol (Calbiochem). Images were captured using an Olympus BX41 microscope with an Olympus camera DP-70 (Olympus Denmark A/S). For immunofluorescence, after antigen retrival, slides were pretreated with 0.1% Triton X-100 for 15 min, 1 M glycine for 30 min and blocking solution (1% BSA and 0.1% Triton X-100) for 1 h. Sections were then incubated overnight at 4 °C with the following primary antibodies in blocking solution: anti-tau clone HT-7 (1:50, MN1000 from Thermo Scientific), anti-ubiquitin (1:100, Z0458 from Dako), anti-SRSF6 (1:200, LS-B5712 from LSBio) and anti-huntingtin clone EM48 (1:1,000, MAB5374 from Millipore). The following day, sections were washed in PBS. Next, sections were incubated in avidin-biotin complex using the Elite Vectastain kit (Vector Laboratories) for 1 h, and, after that, sections were incubated with Streptavidin-Alexa 488 (1:500, Invitrogen) and donkey anti-rabbit Alexa 555 (1:500, Invitrogen) secondary antibodies for 1 h. Nuclei were counterstained with DAPI (1:4,000, Calbiochem). Finally, sections were incubated with Sudan Black for 10 min and mounted on glass slides, coverslipped with DePeX (Serva) and maintained at 4 °C. Images were acquired with a laser confocal LSM710 system coupled to the invert Axioobserver microscope with a 63×, 1.4 numerical aperture npg
